ArticleCanadian journal of gastroenterology & hepatology2019
Association between Smoking and Liver Fibrosis among Patients with Nonalcoholic Fatty Liver Disease.
Article in Canadian journal of gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Smoking and Risk of Hepatic Steatosis Within the MASLD Spectrum in Korean Young Adults.Journal of gastroenterology and hepatology · 2026Article
- Intergenerational and individual effects of smoking exposure on non-alcoholic fatty liver disease: A Mendelian randomization study.Tobacco induced diseases · 2026Article
- Ultrasonographic and elastographic findings of the liver of dogs exposed to cigarette smoke.Brazilian journal of veterinary medicine · 2026Article
- Magnitude and factors associated with chronic liver disease among adults (≥ 18 Years) attending gastroenterology and hepatology clinics in selected public hospitals, West Arsi Zone, Ethiopia: a cross-sectional study.BMC public health · 2025Article
- Ramadan Fasting and Complications of Metabolic Dysfunction-Associated Steatotic Liver Disease: Impacts on Liver Cirrhosis and Heart Failure.Journal of clinical medicine · 2025Review
- Article
- A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases.Therapeutic advances in gastroenterology · 2025Article
- Observational
- Contribution of Sex Differences to the Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD).International journal of translational medicine (Basel, Switzerland) · 2024Article
- Ramadan Fasting in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Transplant, and Bariatric Surgery: A Narrative Review.Journal of clinical medicine · 2024Review
- Effects of nicotine on microRNA-124 expression in bile duct ligation-induced liver fibrosis in rats.BMC pharmacology & toxicology · 2024Article
- Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma.Clinical Medicine Insights. Oncology · 2024Article
- A Mendelian randomization study on the causal effects of cigarette smoking on liver fibrosis and cirrhosis.Frontiers in medicine · 2024Article
- Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions.Life metabolism · 2023Review
- An emerging probiotic with liver health benefits for smokers.Life metabolism · 2023Article
- Article
- Article
- Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.Nature reviews. Endocrinology · 2022Review
- Article
- Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed at analyzing the role of smoking in hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) and at exploring the related risk factors. Methods: This was a cross-sectional study that included a total of 225 patients with NAFLD. Among them, 127 were nonsmokers and 98 were smokers. Liver significant fibrosis was diagnosed when the liver stiffness (LS) value was higher than 7.4 kPa. The diagnostic criterion for NAFLD was a controlled attenuation parameter (CAP) value of >238 dB/m. The CAP and LS values were measured using FibroScan. Results: FibroScan showed that the LS value in the smokers was significantly higher than that in the nonsmokers (10.12 ± 10.38 kPa vs. 7.26 ± 6.42 kPa, Conclusion: This study showed that smoking was closely associated with liver fibrosis among the patients with NAFLD. For patients with NAFLD who smoke, priority screening and timely intervention should be provided if they are at risk of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.